Risk Factor of Recurrence Graves’ Disease after Treated with Anti-thyroid Drug in Damnoen Saduak Hospital
Keywords:
Graves' disease, Anti-thyroid drugs, Disease recurrenceAbstract
This retrospective cohort study aims to evaluate risk factors influencing the recurrence of Graves' disease (GD) in patients following treatment with anti-thyroid drugs (ATD) at Damnoen Saduak hospital, Ratchaburi. Data were collected from the medical records of 110 patients. The research instrument were medical records using individual data records, laboratory results, treatment details, and outcomes. Statistical methods employed for data analysis included chi-square tests, independent t-tests, and logistic regression analysis. The findings indicated that:
The group of patients with recurrence of Graves' disease (GD) after treatment with antithyroid drugs was age, pre-treatment FT3, and FT4 levels, as well as the duration until reaching the minimum drug dose before cessation, were significantly different between patients experiencing GD recurrence post ATD treatment and those who achieved cure. Nevertheless, conducting logistic regression analysis considering the factors mentioned above, it was observed that as age increases, there is a significant reduction in disease recurrence. A predictive equation was formulated to estimate recurrence probability, achieving an accuracy rate of 72.70%.
From this study, age affects the recurrence of the GD. Younger patients had more recurrence than older patients. Choosing a treatment method for patients with GD should use the drug as a consideration for the treatment modality.
References
Benjamin, J. G. (2021). Age and Sex Predict Severity, Remission, and Recurrence in Graves' Disease. Clinical Thyroidology, 33(6), 260-262. https://doi.org/10.1089/ct.2021;33.260-262
Chumchuen, P., Vongkasem, V., & Chumchit, C. (2020). Prevalence and Factors Associated with Positive Thyrotropin Receptor Antibody in Graves’ Disease Patients at Damnoen Saduak Hospital : A Prospective Study. Region 4-5 Medical Journal, 39(4), 592-603.
George, J.K., Luigi, B., Lazlo, H., Laurence, L., Kris, P., & Simon, H.P. (2018). 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European thyroid journal, 7(4), 167-186. https://doi: 10.1159/000490384
He, S., Rongrong, S., Yifang, H., Xiaoyun, L., Lin, J., Zhongmin, W., & Dai, C. (2020). Risk Factors for the Relapse of Graves’ Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis. Clinical Therapeutics, 42(4), 662-675. https://doi: 10.1016/j.clinthera.2020.01.022
Kiatpanabhikul, P. (2021). Relapse Rate and Clinical Risk Factors Affecting the Treatment of Graves’ Disease. Siriraj Medical Journal, 73(7), 451-461. https://doi: 10.33192/Smj.2021.59
Kronzer, V.L., Bridges Jr, S.L., & Davis, J.M. (2021). Why women have more autoimmune diseases than men: An evolutionary perspective. Evolutionary Applications, 14(3), 629-633. https://doi: 10.1111/eva.13167
Lin, L., Hongwen, L., Yang, L., Changshan, L., & Chu, X. (2016). Predicting relapse of Graves’ disease following treatment with antithyroid drugs. Experimental and Therapeutic Medicine, 11(4), 1453-1458. https://doi: 10.3892/etm.2016.3058
Sami, A.L., Houda, A.K., & Salaheldin. (2018). Predictors of Relapse in Graves’ Hyperthyroidism after Treatment with Antithyroid Drugs. Ibnosina Journal of Medicine and Biomedical Sciences, 10(6), 205-208. https://doi: 10.4103/ijmbs.ijmbs_75_18
Srichomkwan, P., & Kingphet, K. (2019). Hyperthyroidism. In Buranathapkajorn, P (Ed.), Endocrine and Metabolic Diseases (pp. 124-144). Text and Journal Publication Company Limited.
Suyeon, P. Eyun, S., Hye-Seon, O., Mijin, K., Min, J.J., Won, G.K., Tae, Y.K., Young, K.S., Doo, M.K., & Won, B.K. (2019). When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’s disease be discontinued. Endocrine, 65(2), 348-356. https://doi: 10.1007/s12020-019-01987-w
Tristan, S., Hannah, F., Alexander, K., Larissa, G., Christian, D., Beat, M., & Philipp, S. (2017). Can we predict relapse in Graves’s disease? Results from a systematic review and meta-analysis. European journal of endocrinology, 176(1), 87-97. https://doi: 10.1530/EJE-16-0725
Xander, G. V., Erik, E., Zwinderman, A.H., Jan, G.P., & Wilmar, M.W. (2016). Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves’ Hyperthyroidism. The Journal of clinical endocrinology and metabolism, 101(4), 1381-1389. https://doi: 10.1210/jc.2015-3644
Downloads
Published
Issue
Section
License
Copyright (c) 2024 ฺ

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารนี้ถือว่าเป็นลิขสิทธิ์ของวิทยาลัยพยาบาลบรมราชชนนี ราชบุรี และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
